Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Saved in:
| Title: | Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. |
|---|---|
| Authors: | Wines BD; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia., Kurtovic L; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia., Trist HM; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia., Esparon S; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia., Lopez E; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Chappin K; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia., Chan LJ; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Mordant FL; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Lee WS; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Gherardin NA; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Patel SK; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia., Hartley GE; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia., Pymm P; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Cooney JP; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Beeson JG; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.; Department of Microbiology, Monash University, Clayton VIC, Australia., Godfrey DI; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Burrell LM; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia., van Zelm MC; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Alfred Hospital, Melbourne, VIC, Australia., Wheatley AK; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.; Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Melbourne, VIC, Australia., Chung AW; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Tham WH; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Subbarao K; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.; World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia., Kent SJ; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.; Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Melbourne, VIC, Australia.; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia., Hogarth PM; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. |
| Source: | Frontiers in immunology [Front Immunol] 2022 Jul 28; Vol. 13, pp. 889372. Date of Electronic Publication: 2022 Jul 28 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
